Tumor mutational burden and response rate to PD-1 inhibition
M Yarchoan, A Hopkins, EM Jaffee - New England Journal of …, 2017 - Mass Medical Soc
M Yarchoan, A Hopkins, EM Jaffee
New England Journal of Medicine, 2017•Mass Medical SocTumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
The New England Journal Of Medicine